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Abstract Methamphetamine (METH) is a frequent drug of
abuse in U.S. populations and commonly associated with
psychosis. This may be a factor in frequent criminal justice
referrals and lengthy treatment required by METH users.
Persecutory delusions and auditory hallucinations are the
most consistent symptoms of METH-associated psychosis
(MAP). MAP has largely been studied in Asian populations
and risk factors have varied across studies. Duration,
frequency and amount of use as well as sexual abuse,
family history, other substance use, and co-occurring
personality and mood disorders are risk factors for MAP.
MAP may be unique with its long duration of psychosis
and recurrence without relapse to METH. Seven candidate
genes have been identified that may be associated with
MAP. Six of these genes are also associated with suscep-
tibility, symptoms, or treatment of schizophrenia and most
are linked to glutamatergic neurotransmission. Animal
studies of pre-pulse inhibition, attenuation of social
interaction, and stereotypy and alterations in locomotion
are used to study MAP in rodents. Employing various
models, rodent studies have identified neuroanatomical and
neurochemical changes associated with METH use.
Throughout this review, we identify key gaps in our
understanding of MAP and suggest potential directions for
future research.
Keywords Candidate genes.Drug addiction.
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Introduction
Methamphetamine (METH), a member of the amphetamine
family of drugs of abuse, is easily manufactured and readily
available in the USA. In 2008, approximately 13,000,000
or 5% of persons age 12 and older in the USA reported
having used METH in their lifetime. While this decrease
from 6.5% in 2002 (NSDUH 2009) is significant, sub-
groups remain particularly vulnerable to METH use
disorders (MUD). For example, rural persons are more
likely to use the drug than persons in either small or large
metropolitan areas; and a recent analysis of the National
Survey on Drug Use and Health noted that METH use
increased as the setting became more rural (Lambert et al.
2008). Of concern, young adults in rural areas were nearly
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p<0.001) to have used METH. Additionally, non-Hispanic
whites entering Substance Use Disorders (SUD) treatment
are most likely to identify opiates and marijuana as their
illicit drugs of choice; whereas, Hispanic and Asian
Americans are more likely to identify METH/amphetamine
as their primary drug of choice (SAMHSA 2009). Lastly,
gay and bisexual men use METH at much higher rates than
other populations (Shoptaw et al. 2003). Significantly, U.S.
youth had the second highest rate of amphetamine use
worldwide in 2007 (UNODC 2009). Additionally, persons
with METH use disorders entering SUD treatment are more
likely to be referred by the criminal justice system than all
other SUD admissions combined (59 versus 38%) and over
twice as likely to receive long-term residential treatment
than all other admissions (17 versus 8%) (SAMHSA 2009).
It is unknown why METH use results in greater criminal
justice-related admissions or longer treatment stays, but
drug-associated psychotic symptoms may have a role in the
drug’s unique behavioral effects. While amphetamines such
as METH can precipitate and exacerbate psychotic symp-
toms in persons with schizophrenia (Batki and Harris
2004), it has long been recognized that such drug use can
produce psychotic symptoms even in persons with no
history of a primary psychotic disorder (Chen et al. 2003;
McKetin et al. 2006). With these issues in mind, the goals
of this review are to describe the risk factors, frequency,
symptoms, and clinical implications of METH-associated
psychosis (MAP), discuss candidate genes with significant
associations, and review preclinical animal research that
aims to simulate an understanding of MAP. Within each of
these areas, we will discuss gaps in our current knowledge
and potential directions for future research.
Clinical features
Natural history and epidemiology of MAP
METH, cocaine, cannabis, alcohol, hallucinogens, seda-
tives, and heroin have all been implicated in substance-
induced psychosis (Caton et al. 2005; van Os et al. 2002;
Fergusson et al. 2003; Arseneault et al. 2004; Manschreck
et al. 1988). Historical features such as psychotic symptoms
presenting before onset of substantial substance use or
psychotic symptoms only occurring in the context of
s u b s t a n c eu s ea r eu s e f u li ne stablishing a diagnosis.
However, in many clinical settings the history is less clear
and discriminating between psychoses that are secondary to
substance use such as METH and those that are primary
psychotic illnesses in a substance-using individual can be
diagnostically challenging. In a study of 400 subjects
recruited from five psychiatric emergency departments with
at least one psychotic symptom and some substance use in
the previous 30 days, 44% of subjects were diagnosed with
a substance-induced psychosis while 56% were diagnosed
with primary psychosis. The Psychiatric Research Interview
for Substance and Mental Disorders (PRISM), which
employs the Diagnostic and Statistical Manual of Mental
Disorders (DSM-IV) criteria for psychotic disorders, was
utilized to discriminate between substance-induced and
primary psychosis. Of note, a diagnosis of primary
psychosis was made if there was “no evidence of heavy
substance use or withdrawal, when psychotic symptoms
persisted for at least 4 weeks in the absence of heavy
substance use, or when psychotic symptoms preceded onset
of heavy use.” Parental substance abuse, drug dependence
(rather than abuse or use), and visual hallucinations were
predictive of a substance-induced psychosis. Additionally,
persons with substance-induced psychosis had lower
Positive and Negative Syndrome Scale (PANSS) scores,
greater awareness of psychotic symptoms and were more
likely to have suicidal ideation (Caton et al. 2005).
Similarly, in a small study (N=19) of stimulant (cocaine
or amphetamine) abusers seen in an emergency setting with
psychotic symptoms determined by the Structured Clinical
Interview for DSM-IV, positive rather than negative
psychotic symptoms predominated with all participants
reporting persecutory delusions, and most having delusions
of reference and some form of hallucinations (Harris and
Batki 2000). While these studies are useful in characteriz-
ing substance use-related psychosis, as will be discussed
later in relation to METH, utilizing duration of psychotic
symptoms as a key determinant in distinguishing primary
psychosis from substance-induced psychosis may not be
valid in all clinical settings.
MAP has been most consistently described in Japanese
populations typically associated with longstanding METH
use and characterized as resembling paranoid schizophre-
nia. Attempting to distinguish psychiatric disease symp-
toms that are appropriate to the situations within which
METH users typically find themselves (purchasing, using,
distributing and/or manufacturing the drug or engaging in
other illegal activities), those symptoms which are
unmasked by METH use but are related to an underlying
psychotic illness (e.g., schizophrenia), and those symptoms
which are secondary to the drug itself can be challenging.
Nevertheless, a subset of METH users develops frank
psychotic symptoms across a range from mild paranoia to
hallucinations or unusual thought content.
In previous studies of METH users, Japanese, Taiwanese,
Australian, and U.S. investigators have identified factors
associated with MAP. In early Japanese studies (published
1955–1992), longer duration and more frequent METH use
were associated with MAP (Ujike and Sato 2004). Of note,
during this time period, Japanese METH users typically used
114 J Neuroimmune Pharmacol (2012) 7:113–139METH exclusively in contrast to the poly-drug use seen in
typical U.S. METH users (Ujike and Sato 2004). In 2003,
Chen characterized three groups of Taiwanese METH users
who were either hospitalized or in a detention center: those
with no history of any psychotic symptoms, those with brief
psychosis (less than 1 month after last METH use), and those
with prolonged psychosis (psychosis which persisted more
than 1 month after last METH use). In this study, those with
MAP had earlier first METH use and used larger amounts of
METH than those who had no history of psychotic
symptoms. There was no difference in duration of METH
use between the psychosis and non-psychosis group. There
were, however, significant pre-morbid schizoid/schizotypal
personality trait scores in those with METH-associated
psychosis, and there was a significant linear correlation
between these trait scores and presence and duration of
psychosis. Additionally, the psychosis group had greater
alcohol dependence, anti-social personality disorder (ASPD),
and major depression (MDD) (Chen et al. 2003). In the same
population, the first-degree relatives of those with psychosis
were more likely to have schizophrenia than those METH
users who had never had psychosis (OR=5.4, 95% CI: 2.0–
14.7, p<0.001). Further, the risk for schizophrenia in the first
degree relatives of those with prolonged psychosis was
greater than those METH users with brief psychosis (OR=
2.8, 95% CI: 1.0–8.0, p=0.042). Chen noted that the greater
the “familial loading for schizophrenia, the more likely a
METH user is to develop psychosis and the longer that
psychosis is likely to last” (Chen et al. 2005).
In an Australian study of community METH users,
McKetin found that MAP typically occurred in the context
of METH abuse or dependence rather than “recreational”
METH use. In METH users with no prior history of
psychosis, the prevalence of psychosis among dependent
users was 27% as compared to 8% in non-dependent users.
However, daily METH use, injection use, and socio-
demographic factors were not associated with METH
psychosis (McKetin et al. 2006). In Japanese and Australian
studies, method of METH administration (injection versus
smoking) did not affect frequency of psychosis (Matsumoto
et al. 2002; McKetin et al. 2008). In a study of adults with
METH dependence in SUD treatment in the U.S., sexual
abuse, greater frequency of recent METH use, and METH
use combined with other drug use were associated with
psychotic symptoms (Christian et al. 2007). In another U.S.
study (N=39) of persons with METH dependence who
reported either frequent or infrequent psychosis while
intoxicated on METH, there was no difference between
the two groups in measures of intelligence, education, age
of first METH use, or duration of METH use. However,
those with frequent psychosis reported greater childhood
attention deficit disorder (ADHD) and family history of
psychiatric illness. Of the participants who had a positive
family history for psychiatric illness, 67% had frequent
psychotic episodes (Salo et al. 2008). In a small U.S. study
(N=19) of individuals being seen in an emergency setting,
higher quantitative plasma METH and amphetamine levels
were associated with more severe psychotic symptoms, but
not to reported amounts of METH ingestion (Batki and
Harris 2004). These studies did not identify factors which
were consistently associated with MAP. However, the
variability in the populations studied (e.g. community v.
hospitalized), methamphetamine severity (use v. dependence)
or use histories (single drug v. poly-drug) may have
contributed to this inconsistency.
WhileMETHpsychosishasbeendiscussedinthemedical
literature since the 1950s, previous studies examining the
frequency of MAP have employed varying definitions of the
disorder. Additionally, not all of the studies used standard-
ized instruments to measure psychotic symptoms or de-
scribed the time period (e.g., lifetime, current) within which
psychosis was examined. Further, many of these studies
(written in Japanese) are not accessible to all investigators.
However, in a summary article, Sato noted that in previous
Japanese studies more than 76% of METH users had a
“paranoid psychotic state with hallucinations” (Sato 1992).
In a comparison of non-treatment seeking cocaine- and
METH-dependent men and women, METH-dependent
individuals were more likely to report psychotic symptoms
than cocaine-dependent men and women (Mahoney et al.
2008). While noting the above limitations in definition and
diagnosis, as well as the variety of populations studied, in
recent studies between 26 and 46% of persons with METH
dependence have MAP (see Table 1).
Signs and symptoms of MAP
While it has been difficult to identify factors consistently
associated with MAP or to precisely determine the
frequency of MAP, the characterization of MAP symptoms
across populations has been quite consistent. Multiple
studies in Japanese (Akiyama 2006), Taiwanese (Chen et
al. 2003), Australian (McKetin et al. 2006), and Thai
(Srisurapanont et al. 2003) populations have described with
remarkable consistency a high frequency of persecutory
delusions and auditory hallucinations in persons with
METH-related psychosis. Other frequently reported symp-
toms were delusions of reference, visual hallucinations, and
thought broadcasting (Chen et al. 2003; Srisurapanont et al.
2003; Akiyama 2006). Ujike and Sato contend that there is
a progression of MAP with an initial phase of psychotomi-
metic effects such as stimulation and heightened concen-
tration, followed by “prepsychosis” with delusions, which
may then progress to frank psychosis with hallucinations
and delusions of reference (Ujike and Sato 2004). In a
study of 149 METH users, the average latency from first
J Neuroimmune Pharmacol (2012) 7:113–139 115use of METH to onset of psychosis was 5.2 years (Ujike
and Sato 2004), while a study comparing METH smokers
and METH injectors found a latency of 1.7 years in
smokers and 4.4 years in injectors (Matsumoto et al.
2002). Severity of psychotic symptoms has been associated
with frequency of METH use, METH injection (Zweben et
al. 2004), and severity of METH craving (Nakama et al.
2008).
Most episodes of substance-induced and MAP are of
brief duration and resolve as substance levels diminish.
However, Japanese investigators have reported that while
MAP may be transient with recovery within 1 month of last
METH use, METH psychosis may also be prolonged,
persisting for longer than 6 months (Ujike and Sato 2004),
and may persist despite drug abstinence (Akiyama 2006).
Western investigators have been more hesitant to attribute
persistent psychotic symptoms solely to substance use and
this is reflected in the diagnostic lexicon of the Diagnostic
and Statistical Manual-IV which defines substance-induced
psychosis as persisting for 1 month or less after last
substance use (APA 2000). In contrast, in a Japanese study
of 104 hospitalized METH users with no prior history of
non-METH-related psychosis, 52% of participants’ psy-
chotic symptoms abated within 1 week; whereas, in 26% of
participants symptoms persisted for more than 1 month and
in 16% of participants symptoms persisted for more than
3 months. Symptoms of psychosis were similar between the
transient (duration<1 week) and persistent (duration>
3 months) groups except that persons with persistent
psychosis reported greater non-auditory and non-visual
hallucinations (Iwanami et al. 1994). In a Taiwanese study
of 174 METH users with psychotic symptoms, 17% had
psychosis despite being abstinent for more than 1 month
(Chen et al. 2003). In both studies, study participants were
abstinent and had no history of schizophrenia or prior
psychoses. It is unclear if long duration of MAP reflects the
drug’s ability to cause a chronic psychotic disorder or if
METH is unmasking a psychotic disorder in persons with
an underlying psychotic diathesis. As previously noted,
chronic psychotic symptoms associated with METH are
more likely to occur in those with a family history of
schizophrenia or in persons with a premorbid schizoid/
schizotypal personality (Chen et al. 2003, 2005). Addition-
ally, a previous neurological disorder (head injury, ADHD,
prematurity, learning disability) may increase the risk of
treatment-resistant psychosis in METH users (Fujii 2002).
Individuals with a brief METH-related psychosis may
relapse to MAP with resumption of METH use or with a
stressor such as severe insomnia or heavy alcohol use
without METH consumption (Sato 1992; Yui et al. 2000;
Ujike and Sato 2004). When MAP recurred with re-
exposure to METH the symptoms were nearly identical to
those in previous psychotic episodes (Sato 1992). If relapse
to psychosis follows METH use, it typically occurs
promptly with 60% of METH users relapsing in less than
1 week and 80% relapsing within 1 month. Spontaneous
Table 1 Frequency of METH associated psychosis
Population studied Time period % Psychotic
symptoms
Psychosis
definition
Reference
US gay & bisexual treatment-seeking METH
abuse/dependent men 18–65 years
Lifetime 26.5% SCID Shoptaw et al. 2003
Australian community METH users >16 years Past Year 13% BPRS McKetin et al. 2006
METH dependent 27%
Non-METH dependent 8%
Taiwanese incarcerated adolescent METH users Past Year 7.5% K-SADS-E Yen and Chong 2006
U.S. adults in treatment for METH dependence Lifetime 36% MINI Grant et al. 2007
Rural 45%
Urban 29%
US METH dependent adults in treatment
(didn’t distinguish between METH-
induced or primary psychotic disorders) Past or current 12.9% MINI Glasner-Edwards et al. 2008
Rural Australian community volunteers >16 years
with METH dependence
Lifetime 46% Self-reported Wallace et al. 2009
U.S. community and in-treatment METH
dependence
Lifetime 45% MEQ Leamon et al. 2010
BPRS Brief psychiatric rating scale; K-SADS-E Kiddie epidemiologic version of schedule for affective disorders and schizophrenia; MEQ
METHamphetamine experience questionnaire
MINI Mini-International neuropsychiatric interview; SCID Structured clinical inventory for DSM-IV
116 J Neuroimmune Pharmacol (2012) 7:113–139relapse usually occurred in persons with greater than 2 years
of METH abuse and vulnerability to relapse provoked by
re-use of METH persists for years (Ujike and Sato 2004).
Treatment of MAP
In multiple prior studies, the presence of both psychiatric
illness and substance use worsened SUD treatment outcome
(Rounsaville et al. 1991; Moos et al. 1994; Weisner et al.
2000). In a study of 526 METH dependent adults,
individuals with any history of psychotic disorder at the
3-year follow-up were more than twice as likely to have
been hospitalized in the previous 12 months, had more total
hospitalizations, had greater severity of their psychiatric
symptoms, and were more likely to have attempted suicide
than participants with no history of psychosis. However, the
two groups did not differ in their duration of SUD treatment
attendance, treatment retention, or METH use. This study,
however, did not distinguish between primary and
substance-induced psychosis and those who required
hospitalization were not eligible for study enrollment
(Glasner-Edwards et al. 2008). Also of note, in a study of
paranoia in community and in-treatment METH users, 37%
of those persons with paranoia obtained a weapon, 11%
used a weapon, and 15% attacked another person (Leamon
et al. 2010). Only one randomized controlled trial evaluated
anti-psychotics in persons with amphetamine-related psy-
chosis. In this 4-week study, there was no significant
difference in clinical efficacy between olanzapine and
haloperidol (Leelahanaj et al. 2005).
Needs in clinical research
Studies of risk factors for MAP have largely been done in
Japanese, Taiwanese, and Australian populations. It is
unknown iffindingsfromthese large studies are generalizable
to other populations such as those in the U.S. given the likely
differences in use patterns, socio-environmental factors, and
genetics. A single large study of U.S. METH users examined
abuseandMETHusecharacteristicsandtheirassociationwith
psychosis. However, there are no studies of factors such as
perceived stress or cultural stress which have been identified
in other populations as being factors in the development of
psychoses. Similarly, there are no studies of any kind
assessing protective factors for MAP, which may mitigate
against risk factors. Of note, none of the above studies
examined sleep deprivation as a factor in the genesis of MAP,
a factor that is well-described as a stressor which can result in
psychosis. Additionally, there are no studies examining what
role preexisting conditions, socio-environmental stressors or
protective factors play inthe severity, persistence or relapse of
MAP. Lastly, little is known about the prevention of persistent
and recurrent MAP.
Susceptibility genes
MAP is likely a complex genetic disease in which
environmental factors interact with multiple polymorphic
genes to influence susceptibility. Several studies have
reported associations between MAP and genetic variation,
including single nucleotide polymorphisms (SNPs), vari-
able number tandem repeats (VNTRs), and insertion/
deletions (I/D) (see Table 2). The candidate genes listed in
Table 2 were selected based on a wide range of evidence,
such as biological function, differential expression in
disease, involvement in schizophrenia, which is considered
pharmacologically similar to MAP, and findings from
animal models. In these studies, allele frequencies were
compared in unaffected and affected individuals. Unaffected
individuals were generally healthy individuals without a
history of psychosis-related disorders. Affected individuals
were diagnosed using the ICD-10 or the DSM-IV criteria and
were primarily individuals with METH dependence and
psychosis (20% of studies reported individuals with METH
abuse and psychosis). Of note, several studies consisted of
heterogeneous populations that included individuals with and
without psychosis. (These populations are annotated as such
in Table 2.) Another phenotype often considered in these
studies was the clinical course of MAP. The prognosis of
MAP varied among individuals, some of whom showed
continued psychotic symptoms, even after METH was
discontinued. Accordingly, the individuals were categorized
based on the duration of the psychotic state after METH
discontinuation. Transient psychosis was defined as symp-
toms that improved within 1 month of METH discontinua-
tion and the start of treatment with neuroleptics; whereas, the
prolonged type was defined as psychotic symptoms continu-
ing for more than 1 month after METH discontinuation and
the treatment of neuroleptics. The hypothesis-driven studies
investigating putative candidate genes and their association
with psychosis among METH-dependent individuals are
summarized in Table 2. Recognizing the high probability of
false-positive associations due to multiple comparisons, we
chose to focus on candidate genes with significant associa-
tions, i.e., pv a l u e <0.001. There were seven genes in this
category: D-amino acid oxidase activator, Dystrobrevin-
Binding Protein 1, Frizzled 3, Metabotropic Glutamate
Receptor 2, 5-Hydroxytryptamine (serotonin) Receptor 1A,
Prokineticin Receptor 2, and Glycine Transporter 1.
D-amino acid oxidase activator (DAOA) DAOA is the
gene encoding the d-amino acid oxidase activator. DAOA is
expressed in multiple tissues including the amygdala,
caudate nucleus, spinal cord and testes (Chumakov et al.
2002). Although the functional mechanisms of DAOA are
not fully understood, DAOA activates D-amino acid
oxidase, which oxidizes d-serine, an endogenous ligand
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J Neuroimmune Pharmacol (2012) 7:113–139 125for the glycine site of the N-Methyl-D-aspartate (NMDA)
type glutamate receptor (Chumakov et al. 2002). D-serine
levels are low in schizophrenic patients and administration
of D-serine has been shown to reduce some of the
symptoms of this disease (Kantrowitz et al. 2010). This
provides a potential link between DAOA and the glutamate
hypo-function hypothesis of schizophrenia, which integra-
tes environmental influences and causative genes, is based
on clinical and neuropathological evidence of the hypo-
function of glutamatergic signaling via NMDA receptors.
The DAOA gene is located on chromosome 13q and has
been found to be a susceptibility locus for schizophrenia
(Badner and Gershon 2002), and many studies have found
an association between genetic variants in DAOA and
schizophrenia (Chumakov et al. 2002; Schumacher et al.
2004; Yue et al. 2007). In a case-controlled study, Kotaka et
al. (2009) demonstrated an association between a DAOA
polymorphism (rs778293; p=0.0002) and psychosis among
METH-dependent subjects. This polymorphism was previ-
ously shown to be associated with schizophrenia; however,
its functionality is unknown.
Dystrobrevin-binding protein 1 (DTNBP1) DTNBP1 enc-
odes dystrobrevin-binding protein 1 also referred to as
dysbindin. This ubiquitously expressed, coiled-coil-
containing protein is a subunit of the biogenesis of
lysosome-related organelles complex 1 (BLOC-1), which
regulates trafficking to lysosome-related organelles (Li et al.
2003). In muscle and non-muscle cells, DTNBP1 binds to
α- and β-dystrobrevins, components of the dystrophin-
associated protein complex (DPC) (Benson et al. 2001). In
muscle, the DPC is required for the maintenance of muscle
integrity and normal muscle function. In the brain,
dysbindin is most prevalent in axons, particularly those
with large synaptic terminals such as the mossy fiber
synaptic terminals in the cerebellum and hippocampus
(Benson et al. 2001). In a case controlled study, Kishimoto
et al. (2008a) demonstrated an association of a polymor-
phism in the DTNBP1 gene and psychosis among METH-
dependent individuals (rs3213207; p=0.000025). Further-
more, two haplotypes at these loci were also significantly
associated with MAP (p values<0.0015). Significant
associations between schizophrenia and DTNBP1 also have
been reported (Edwards et al. 2008; Straub et al. 2002).
Consistent with this, reduced levels of dysbindin expression
have been associated with the pathogenesis of schizophre-
nia (Talbot et al. 2004; Weickert et al. 2008) and thought to
be related to glutamatergic neurotransmission. In schizo-
phrenic patients, dysbindin-1 is reduced in intrinsic,
glutamatergic terminals of the hippocampus which is
inversely correlated with increased vesicular glutamate
transporter (Talbot et al. 2004). As evidence is mounting
that glutamate hypo-function may be related to the etiology
of schizophrenia (Konradi and Heckers 2003), it is
postulated that DTNBP1 variants may contribute to MAP
through pathways involving glutamatergic neurotransmis-
sion. Despite the many genetic studies of this gene, the link
between functionality of these polymorphisms and dysbin-
din expression has not been investigated.
Frizzled 3 (FZD3) Frizzled proteins are cell surface
receptors for secreted Wnt proteins (Wang et al. 2006a).
Both frizzled and Wnt proteins are thought to be important
in central nervous system (CNS) development. FZD3, the
human Frizzled-3 gene, is widely expressed in the
developing nervous system and is involved in axonal
growth and guidance (Wang et al. 2006b). Wnt signaling
plays a role in axonal remodeling and synaptic differenti-
ation in the cerebellum (Cadet and Krasnova 2009; Lucas
and Salinas 1997) and abnormal Wnt signaling has been
linked to schizophrenia (Cotter et al. 1998). FZD3 maps to
chromosome 8p21 and consists of eight exons. The 8p22-
21 region has been identified as a susceptibility locus for
schizophrenia in several studies (Blouin et al. 1998;
Gurling et al. 2001; Pulver et al. 1995). However, genetic
studies with the Frizzled-3 gene and schizophrenia have
been contradictory, with both positive and negative associ-
ations among Han Chinese (Yang et al. 2003), Japanese
(Zhang et al. 2004), and Korean (Jeong et al. 2006)
populations. Interestingly, the association between
Frizzled-3 and MAP has only been observed with hap-
lotypes (p<0.00002) and not at the individual loci, which
may indicate a required synergism between the polymor-
phisms for a phenotypic effect (Kishimoto et al. 2008b).
Metabotropic glutamate receptor 2 (GRM2) GRM2 is
another gene involved in glutamatergic neurotransmission
and found to be significantly associated with MAP (Tsunoka
et al. 2010). GRM2 is located on chromosome 3p in a region
linked to schizophrenia in several studies (Badner and
Gershon 2002;P u l v e re ta l .1995). GRM2 encodes the
group II metabotropic glutamate receptor 2 (mGlu2). mGlu2
is a G-protein coupled receptor involved in inhibition of
adenylate cyclase and cAMP formation (Cartmell et al.
1999) and the major presynaptic group II autoreceptor
activated by synaptically released glutamate (Kew et al.
2002). Although another group II metabotropic glutamate
receptor, glutamate receptor 3 (mGlu3), has been implicated
in etiological, pathophysiological and pharmacotherapeutic
aspects of schizophrenia (Harrison et al. 2008;L y o ne ta l .
2008; Sartorius et al. 2008), no statistically significant
association with GRM2 and schizophrenia was found in the
Japanese population (Joo et al. 2001).
5-Hydroxytryptamine (Serotonin) receptor 1A (5-HT1A) 5-
HT1A, the gene encoding the 5-HT receptor 1A, is a G
126 J Neuroimmune Pharmacol (2012) 7:113–139protein-coupled receptor which is widely expressed in the
brain, including in the hypothalamus, hippocampus, and
cortex. Through serotonin (5-HT) binding, this receptor
mediates inhibitory neurotransmission. The serotonin sys-
tem has been shown to be important in the neural
processing of anxiety and the neurobiological control of
learning and memory. Similar to the glutamatergic pathway,
altered serotonergic neurotransmission is speculated to
contribute to schizophrenia susceptibility. Evidence sug-
gests that METH, which acts as a substrate for the 5-HT
transporter, elevates extracellular 5-HT levels by both
promoting the efflux via transporter-mediated exchange
and by increasing cytoplasmic levels by disrupting storage
of 5-HT in vesicles (Cadet and Krasnova 2009; Rothman
and Baumann 2003). Although studies have explored
whether there is an association between several of the
genes involved in 5-HT regulation and MAP, only the
rs878567 polymorphism in the 5-HT1A receptor was
significantly associated using an alpha level of 0.001 as
significant (Kishi et al. 2010). Polymorphisms in the 5-
HT1A receptor have been associated with schizophrenia in
several studies (Huang et al. 2004; Le Francois et al. 2008;
Lemonde et al. 2003, 2004), including the rs878567
polymorphism. Currently, 5-HT(1A) receptor agonists are
being considered for the treatment of schizophrenia
(McCreary and Jones 2010).
Prokineticin receptor 2 (PROKR2) PROKR2 encodes pro-
kineticin receptor 2 (PK-R2), an integral membrane G-
protein coupled receptor for prokineticins. Prokineticins
and their receptors are involved in a wide range of
biological functions in multiple organ systems. In the
CNS, prokineticin 2 modulates neurogenesis, circadian
rhythms, and migration of the subventricular zone-derived
neuronal progenitors (Cheng et al. 2002; Ng et al. 2005).
The involvement of PK-R2 in circadian rhythm raises the
question of whether this gene may be associated with
mood disorders, a phenotype often observed in patients
with drug addiction. Several animal studies have shown
that METH increases expression of circadian genes in the
brain (Iijima et al. 2002). The PROKR2 gene is located
on chromosome 20p12.3, which was shown to be linked to
bipolar disorder in three studies (Detera-Wadleigh et al.
1997; Fanous et al. 2008;R o s se ta l .2008). An association
between PROKR2 gene variants and major depressive
disorder and bipolar disorder was reported in a Japanese
population (Kishi et al. 2009b); however, this study was
small and confirmatory studies will be necessary to
validate this finding. Furthermore, these same investiga-
tors have shown that 3 individual SNPs in the PROKR2
gene (rs6085086, rs4815787, rs3746682), as well their
haplotypes (p≤0.00019), were associated with MAP
(Kishi et al. 2010).
Glycine transporter 1 (SLC6A9) SLC6A9, which encodes
the glycine transporter type 1 (GLYT1), is involved in
glutamatergic neurotransmission, particularly at NMDA-
type glutamate receptors. It is currently believed that
termination of the different synaptic actions of glycine is
produced by rapid re-uptake through two sodium- and
chloride-coupled transporters, GLYT1 (located in the
plasma membrane of glial cells) and GLYT2 (located in
pre-synaptic terminals). GLYT1 regulates both glycinergic
and glutamatergic neurotransmission by controlling the
reuptake of glycine at synapses. The NMDA receptors are
regulated in vivo by the amino acids glycine and D-serine.
Glycine levels, in turn, are regulated by GLYT1, which
serves to maintain low sub-saturating glycine levels in the
vicinity of the NMDA receptors. Competitive antagonists
of NMDA receptors produce a psychotic state in healthy
subjects and exacerbate symptoms in schizophrenics.
SLC6A9 has emerged as a key novel target for the
treatment of schizophrenia. Morita et al. examined SLC6A9
among Japanese subjects with METH-dependence and
psychosis (Morita et al. 2008). Two SNPs conferred an
increased risk for MAP (rs2486001 and rs2248829) in
addition to the haplotype T-G (p=0.000037). It is speculated
that variants of the SLC6A9 gene may affect susceptibility to
MAP by modulating NMDA receptor function.
In summary, there is reasonably strong evidence that
genetic variation in neurotransmitter systems and in neural
development or growth is associated with risk for MAP. Of
the seven genes with strong empirical support for associ-
ation with MAP, four are involved in glutamatergic
neurotransmission (DAOA, DTNBP1, GRM2 and
SLC6A9). Potential epistatic (i.e. gene x gene) interactions
among these glutamatergic genes should be investigated.
Polymorphism in a key gene in serotonin system regulation
and signaling (HTR1A) is also associated with risk for
MAP, which suggests that other 5-HT system genes may
also be good candidates. Finally, two genes with roles in
CNS development (FZD3) and neurogenesis (PROKR2)
may help to identify other genes as well as developmental
processes that mediate vulnerability to MAP.
Gaps in genetic research
These studies reviewed in relation to MAP have examined
candidate genes selected based on current concepts of
neurobiology. Priorities for future genetic research on MAP
include: replicate genetic associations within and across
ethnically diverse populations; adjust for multiple compar-
isons to minimize false-positive associations; utilize linkage
disequilibrium and tagSNP information to capture the
polymorphic structure of candidate genes; increase statisti-
cal power by using larger population cohorts to minimize
false-negative associations; improve phenotyping of MAP
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and account for trajectory of cessation, treatment response
and relapse; identification of allele-specific in vivo activity
in humans and non-human animals.
METH neuropathobiology
Lines of evidence support the notion that METH abuse
leads to neurodegeneration and, as such, may be a
component part of MAP pathobiology (Krasnova and Cadet
2009). The neuropsychological events noted show deficits
in attention, working memory, and decision making in
METH addicts. Bioimaging and histopathologic evalua-
tions show that the clinical findings parallel composite
damage to dopamine and serotonin axons, loss of gray
matter with linked hypertrophy of the white matter and
microgliosis in different brain areas (Kuhn et al. 2008;
Thomas et al. 2004a, b, 2008a, b;X ue ta l .2005). The
molecular basis of such neurotoxicities, interestingly,
parallel neural damage seen in a range of neurodegenerative
disorders that include Alzheimer’s and Parkinson’s disease,
HIV-associated neurocognitive disorders, and amyotrophic
lateral sclerosis. Such neurotoxicity and inevitable neuro-
degeneration parallels the presence of oxidative stress,
excitotoxicity, neuroinflammation, mitochondrial dysfunc-
tion, decreased antioxidants and stress patterns (Cadet and
Krasnova 2009). These effects a host of intracellular
organelle functions and suggests that a range of therapeutic
strategies can be developed that would slow or reverse
adverse neuronal events (Kosloski et al. 2010; Mosley and
Gendelman 2010; Stone et al. 2009).
Animal models
In this section, we review the published preclinical animal
research that aims to simulate or directly understand some
facet of METH-related psychosis. We will not attempt to
survey the vast literature on neurobiologic and neurotoxic
effects of METH exposure as it is beyond the scope and the
focus of the present paper. The interested reader is referred to
the following reviews on these topics (Cadet and Krasnova
2009;F l e c k e n s t e i ne ta l .2007;V o l ze ta l .2007). This section
of the review, however, will have an eye toward the validity
of the animal models that have been used to date, as well as
identifying key gaps in the methods and research that need to
be filled. Given the paucity of animal research directly
focused on questions related to MAP, an important goal of
this section is to make recommendations for future research
that involves the development of translationally-relevant
models that are reliable (i.e., reproducible) and predictive
(Geyer and Markou 1995).
Clearly, establishing animal models that are predictive of
the human phenomenon of interest (MAP in this case) will
not happen without experimental situations and associated
manipulations that are reproducible and consistent within
and across laboratories. We agree with writers that espouse
the best way to this broad form of predictive validity and to
strong translational animal models is to work toward
improving construct and etiological validity (Geyer and
Markou 1995; Markou et al. 2009). For construct validity,
attention to continually improving the match between what
is measured at the behavioral (psychological) and neural
levels in the animal models of MAP with what is believed
to be the behavioral and neural processes underlying this
psychosis in humans (Markou et al. 2009) is essential. As
an example, if the current state of knowledge suggests that
individuals with MAP have impaired sensorimotor gating
that leads to sensory flooding and cognitive fragmentation,
then some insight regarding the human condition may come
from a better understanding of a similar attentional process
in animal models. In this example, pre-pulse inhibition
(PPI) may be of particular import. Pre-pulse inhibition
refers to the decrease in startle response evoked by an
auditory stimulus that is preceded by a pre-pulse stimulus
(usually the startle stimulus at lower intensity and shorter
duration). Deficits in PPI inhibition have been reported in
patients diagnosed with schizophrenia, as well as in rats
pretreated with METH (Abekawa et al. 2008) or have a
history of self-administering METH (Hadamitzky et al.
2011; see later).
The strategy of searching for and establishing construct
validity likely means that no single animal model will be
sufficient to capture all processes relevant to the disorder of
interest in humans. Also, this strategy is inherently
translational. Working toward etiologic validity further
encourages the communication and sharing of ideas,
theories, and methods necessary for successful translational
research (Markou et al. 2009). Etiologic validity refers to
the matching of environmental and physiological precursors
presumably responsible for the onset of the disorder. There
is ongoing debate as to the extent that METH induces
psychotic symptoms versus exacerbating pre-existing
symptoms (see earlier). This is one of many unique
instances in which animal models could serve to inform
this important clinical issue. For instance, will rats
intravenously self-administer enough METH to alter those
behavioral and neural processes altered in humans diag-
nosed with MAP? Are the predisposing factors, whether
environmental, neural, or genetic, thought to be relevant in
human MAP contributing to such effects in the animal
models? Prior research has demonstrated that under some
conditions rats self-administering METH will show deficits
in object recognition memory (Reichel et al. 2011) and PPI
(Hadamitzky et al. 2011). Unfortunately, this research is
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MAP in humans. Given that METH psychosis is associated
with severe behavioral and neuropsychiatric complications
(see earlier), there is a pressing need to definitively and
precisely identify the behavioral and neurobiological
mechanisms underlying the development of METH psy-
chosis. As a result of this identification, behavioral
interventions and psychopharmacological treatment strate-
gies can then be developed.
Despite the limited work, animal studies have consis-
tently shown that many psychological processes underlying
clinical features of METH psychosis can be reproduced in a
variety of animal species, including mice, rats, guinea pigs,
cats and non-human primates (e.g., Japanese monkeys).
Like METH addicts, animals that are chronically treated
with a low (non-toxic) dose of METH gradually develop
psychotic-like symptoms, such as a decrease in motor
activity, an increase in stereotypies, decreased interest to
external stimuli and surroundings, and decreased social
functioning (Kuczenski et al. 2009). Also, some of the
changed behavioral patterns (e.g., behavioral sensitization)
persist even long after the cessation of drug treatment, and
have a tendency to relapse or exacerbation upon re-exposure
to the drug. Furthermore, concurrent antipsychotic drug
treatment can prevent recurrence triggered by METH use
(Misra et al. 2000). These results strongly suggests that
animal models of METH psychosis have high face (e.g.,
similarities to clinical symptoms), construct (e.g., METH use
and associated brain changes), and predictive validity (e.g.,
antipsychotic effect), and are effective in reproducing
behavioral symptoms of human METH psychosis, mimick-
ing the time course of symptom development, and its
liability to exacerbation.
Behavioral characteristics of MAP in nonhuman primates Most
of this work has been carried out by Japanese researchers since
the early 1970s beginning during the decade immediately after
World War II when METH abuse occurred in epidemic
proportions in Japan (Ujike and Sato 2004). Japanese
psychiatrists had observed an increased number of cases of
MAP in chronic METH users and began to investigate the
behavioral characteristics of the psychosis and associated
biochemical mechanisms in animals. Nonhuman primate
models are thought to be better than other species models in
capturing complex and fine-grained behavioral abnormalities
resembling human MAP, especially aspects of perceptual
aberrations, social interaction, and interpersonal relationship.
This is because monkeys, especially Japanese monkeys
(Macaca fuscata) are well known to form a stable and
intricate hierarchical society in which each member follows a
certain rank order appropriate in interacting with others.
An early study provided a vivid description of acute and
chronic effects of METH treatment on a group of Japanese
monkeys (Machiyama 1992). They gave monkeys intra-
muscular METH injection at 1.0 mg/kg from Monday to
Saturday for 3–6 months. At the same time, physiological
saline was given by intramuscular injection to the other
animals that served as controls. Upon acute treatment, some
monkeys showed motor excitation, whereas other showed
motor suppression. They identified that this marked
individual difference was due to the different behavioral
traits of monkeys in the group. Active monkeys that
showed enhanced repetitive motor activity to acute METH
were those aggressive individuals occupying higher ranks
while non-active monkeys, at the bottom in the ranking
order, demonstrated a decrease in motor activity to acute
METH treatment. Over the course of repeated drug
treatment, some monkeys developed behavioral abnormal-
ities in a variety of psychological domains. In the
sensorimotor domain, after about 1 month treatment, some
monkeys displayed a stereotypical body-fingering behavior
which entailed continuous fingering and investigating
certain parts of the body, such as the wrist, thigh, abdomen,
penis, or scrotum (Machiyama 1992). In the perception
domain, after about 2 months of repeated treatment, some
monkey displayed hallucination-like perceptual distortions
(e.g., “staring” at vacant space, floor or certain body parts
of their own or cage mates, and at times touching with
fingers). In the social behavior domain, some monkeys
gradually lost interest in social interaction (e.g., grooming
and mounting), and withdrew to stay in a location in the
cage, and could suddenly show inexplicable aggression and
fear, and broken behavioral response patterns (termed
“splitting”). There were also marked individual differences.
Monkeys, with middle and high ranks that responded
actively to acute METH injection, demonstrated the most
severe behavioral abnormalities in response to chronic
METH treatment. Monkeys with lower ranks fared better
and only exhibited mild changes. Two high ranked
monkeys even died before the entire experiment was
completed. After the termination of daily injections, some
behavioral abnormalities disappeared, while others per-
sisted for an extended period. In general, perceptual
aberrations (e.g., staring, fixation) diminished rather rapidly
and to a greater extent than deficits in sensorimotor (e.g.,
fixating) and social functioning (e.g., social withdrawal).
Also, some monkeys who exhibited persistent behavioral
changes that were easily identifiable by uninformed
observers recovered better than others. Most interestingly,
the psychotic behaviors of chronically treated monkeys
could be re-triggered by a saline injection or a METH
injection, mimicking clinical phenomena of stress and drug
priming-induced relapse of METH psychosis.
One of the issues with these observational studies is the
lack of formal assessments of psychological functions.
Therefore, it is unclear what psychological function(s) (e.g.,
J Neuroimmune Pharmacol (2012) 7:113–139 129attention, working memory, episodic memory, executive
functioning, emotional regulation, etc.) were impaired by
chronic METH treatment that contributed to the observed
behavioral abnormalities. The second issue is that the
experimenter-controlled METH administration regimen
did not mimic human METH use (via self-administration)
and the constant dosing regimen used in the monkey studies
also did not reflect the typical pattern of human METH use.
Most METH abusers start with very low doses of the drug
and have had a long history of progressively escalating
their doses. Thus, human METH psychosis often appears
during the course of escalating dosage of drug administra-
tion (i.e., “binges” or “runs”), and discontinuation of drug
usage usually results in a rapid decline of the psychosis,
closely paralleling urine drug levels (Angrist 1994; Davis
and Schlemmer 1980; Kuczenski et al. 2009). This aspect
of METH use pattern was not mimicked in these early
studies.
There are several issues that may hinder the effort to
delineate the neurobiological underpinnings of METH
psychosis. The first is the lack of validated rodent
behavioral models of METH psychosis. Unlike non-
human primate models, which provide richer behavioral
repertoires sensitive to the psychotomimetic effect of
METH, most rodent studies focus on motor activity and
stereotypy. Behavioral sensitization is taken as signs of
METH psychosis (Martinez et al. 2005; Nestler 2001;
Robinson and Becker 1986; Segal and Mandell 1974; Segal
et al. 1981). One issue with psychomotor sensitization and
stereotypy as behavioral indices of METH psychosis is that
they do not seem to capture the emotional, cognitive, and
perceptual disturbances that characterize human METH
psychosis disorders. Other behavioral abnormalities induced
by repeated METH treatment, such as disruption of PPI of
acoustic startle response, may provide a better model (Braff et
al. 2001). The following section discusses this rodent
research in more detail.
Behavioral characteristics of METH psychosis in mice and
rats To date, the behavioral models explicitly developed for
studying symptoms of MAP in rodents fall into three broad
categories: i) METH-induced deficits in PPI, ii) METH
attenuation of social interactions, and iii) METH induced
stereotypy and alterations in locomotion. The following
narrative will provide an overview of this research and
highlight some key findings that indicate their possible
utility for understanding aspects of MAP in humans.
Pre-pulse inhibition (PPI) Rodents will startle to a sudden
loud sound such as a 40 ms, 120-dB white noise. Under
typical conditions, this startle reaction is reduced if this
startle stimulus is preceded by a shorter and less intense
pre-pulse stimulus (e.g., 20 ms, 72-dB white noise). This
inhibition of the startle is thought to measure sensorimotor
gating (Braff and Geyer 1990). Individuals diagnosed with
schizophrenia show deficits in PPI; an effect that can be
simulated by acute and repeated treatment with METH. For
example, Arai and colleagues found that mice pretreated with
3 mg/kg METH showed reduced PPI (Arai et al. 2008). A
similar acute METH treatment protocol has been shown to
be effective at producing PPI deficits in rats (Maehara et al.
2008). Of note, this deficit in PPI was not seen in mice
treated acutely with 1 mg/kg METH (Arai et al. 2008).
However, in that same report by Arai et al., repeated
treatment with METH (1 mg/kg) for 7 days disrupted PPI
and this deficit persisted after 7 days of abstinence from
METH. More recently, Hadamitzky et al. (2011) report
deficits in PPI in rats that had an extended history of self-
administering intravenous METH. This research reflects an
important advance in developing a translational model to
study aspects of MAP. That is, like humans, this alteration in
sensorimotor gating was self-induced by the rat.
Behavioral pharmacology research investigating the
mechanism of the METH-induced deficits in PPI have
focused either on the effects of established antipsychotic
medications or on the effects of ligands thought to act on
receptor processes involved in aspects of the psychosis.
Along the former lines, the typical antipsychotic medication
haloperidol has been shown to alleviate PPI deficits
induced by acute treatment with METH (Maehara et al.
2008). Further, the atypical antipsychotics olanzapine and
risperidone alleviated PPI deficits induced by repeated
METH treatment (Abekawa et al. 2008). Arai and
colleagues found that the GABAB agonist baclofen allevi-
ated deficits in PPI induced by acute and chronic METH
exposure (Arai et al. 2009). Further, the cholinergic system
appears to be important for METH-induced deficits in PPI.
For example, pretreatment with the muscarinic agonist
oxotremorine blocked METH-induced deficits in PPI
(Maehara et al. 2008). In this same report, the investigators
did not find an effect of the nicotinic agonist nicotine. This
result contrasts with (Mizoguchi et al. 2009) who found that
pretreatment with nicotine alleviated PPI deficits produced
by METH. Further, the nicotinic antagonist dihydro-β-
erythroidine (DHβE) and METHyllycaconitine both
blocked this ameliorative effect of nicotine indicating a
role for α4β2- and α7-containing nicotinic acetylcholine
receptors. The most notable difference in protocol between
these discrepant reports was that Maehara et al. 2008 used
rats; whereas, Mizoguchi et al. 2009 used mice. Regardless,
the comorbidity between METH and tobacco use, as well as
schizophrenia and tobacco use, makes this an important
area for future research.
Social interaction When a rat is paired with a conspecific,
they show a variety of species-specific behaviors. These
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under, and nosing (Barnett 1963). Some researchers have
suggested that alternations in social interaction resulting
from METH exposure may be a useful model to study the
paranoid and social anxiety symptoms of humans with
MAP (Clemens et al. 2004; Rawson et al. 2002). Previous
research has shown that acute METH treatment can alter
social interaction. For example, Shinba et al. 1996 found
that rats treated with either 0.1 or 1 mg/kg METH on
average spent their time further away from the conspecific
in the environment than saline controls [see also (Arakawa
1994)]. Perhaps of more interest from a modeling or
simulation perspective is the more recent work by Clemens
and colleagues showing ‘social withdrawal’ in rats follow-
ing an abstinence period from METH (Clemens et al.
2007a, b). In one study, Clemens and colleagues adminis-
tered METH at 2.5 or 5 mg/kg every 2 h for a total of 4
injections. METH increased general activity in the chamber
across the entire 7.5 h treatment/measurement period
regardless of dose (Clemens et al. 2004). Rats treated with
the highest dose of METH (20 mg/kg total) also developed
head weaving at the end of the treatment period, suggesting
stereotypy with this protocol (see next section). Acute high
dose METH increased activity and head-weaving. Albeit
interesting, the most notable finding from the perspective of
this report is that following 4 weeks of abstinence from
METH these rats had significantly lower social interaction
score than controls. Subsequently, this social withdrawal
finding was extended to a treatment regimen in which rats
were administered 8 mg/kg METH once per week for
16 weeks (Clemens et al. 2007a, b). In fact, the alterations
in social interaction were seen after 7 weeks of abstinence.
Stereotypy and alterations in locomotion As the acute dose
of METH increases, its behavioral effect in rats and mice
generally shifts from inducing hyperactivity to inducing
stereotypy. These effects of METH can become exaggerated
(i.e., sensitization) with repeated treatment (Bevins and
Peterson 2004; Kuczenski et al. 2009; Maehara et al. 2008;
Ujike et al. 1989). Further, a handful of papers published in
the 1960s showed that spontaneous wheel running, activity,
and reactivity to external stimuli are blunted long after (e.g.,
10 weeks) chronic treatment with METH has ceased [see
Utena 1961, 1966); Yagi 1963; Yui et al. 2000 and
Machiyama 1992 for more detailed discussion of this and
related research]. The presentation of such behavioral
alterations that sensitize with repeated treatment and persist
with abstinence has been considered a model for some of
the symptoms of psychosis (Machiyama 1992; Takigawa et
al. 1993; Yui et al. 2000). Converging support for this
notion comes from the overlap in the neurobiological
processes underlying these motor effects of METH and
that of psychosis in humans, as well as behavioral
pharmacologic work indicating the effectiveness of anti-
psychotic medications. For instance, METH-induced loco-
motor stimulation is blocked by clozapine, haloperidol, and
chlorpromazine (Maehara et al. 2008; Okuyama et al.
1997). Notably, METH-induced stereotypy in the work of
Okuyama et al. 1997 was blocked by haloperidol and
chlorpromazine, but not clozapine. Additional pharmaco-
logic research has implicated the serotonergic, dopaminer-
gic, and muscarinic systems in these effects (Balsara et al.
1979; Maehara et al. 2008; Ujike et al. 1989). For instance,
Ujike et al. 1989 found that repeated daily METH treatment
in rats (4 mg/kg for 14 days) increased locomotion and
stereotypy. Pretreatment with dopamine D1 receptor antag-
onists SCH23390 or the D2 receptor antagonist YM-09151-
2 blocked this sensitization.
Most of the repeated or chronic METH exposure
research in this area involves a daily injection of METH
for a prescribed number of days. Notably, a recent study by
Kuczenski et al. (2009) sought to investigate these shifts in
locomotor stimulation and stereotypy in rats, using an
intravenous infusion protocol designed to more closely
mimic the chronic escalating use of METH seen in humans
and simulate the longer half-life of METH in humans (ca.
12 h in human versus 1 h in rats). Their findings confirm
and extend earlier research describing the development of
stereotypy, as well as disruption of sleep, in what seems to
be a more translationally relevant model of MAP. Whether
this is the case or not will need to await further research.
However, one limitation of this model that will need to be
overcome, if this model is to be more widely adopted, is the
high mortality rate of the rats in the escalating METH
exposure phase.
Neurobiological mechanisms underlying MAP
Chronic METH use profoundly changes the brain structures
and chemistry (Chang et al. 2007). Studies on the METH-
induced brain changes relevant to MAP have focused on
the catecholaminergic systems (e.g., dopamine, norepineph-
rine, 5-HT, etc.). This approach makes sense given that
METH is known to cause both acute and chronic
neurotoxic changes in dopaminergic and serotonergic
neurons in animals and humans and that psychosis in
schizophrenia is thought to result from hyperactivity of the
mesolimbic dopaminergic system. Some structural changes
(enlarged lateral ventricle, enlarged basal ganglia, reduced
hippocampal volume), that have been reported in patients
with schizophrenia, have also been found in people who
were chronic METH users, strongly indicating that these
structural changes and their underlying mechanisms may be
responsible for METH psychosis (Chang et al. 2007).
Human postmortem and imaging studies have consis-
tently shown that chronic METH use causes a reduction of
J Neuroimmune Pharmacol (2012) 7:113–139 131dopamine transporter (DAT) density in the various dopami-
nergic systems, including the dorsal striatum, nucleus
accumbens, and prefrontal cortex. However, this pro-
nounced effect persists long after cessation of drug
administration (Sekine et al. 2001, 2003; Volkow et al.
2001c; Wilson et al. 1996). The striatal dopamine D2
density is generally not affected. However, lower level of
D2 receptor availability in the orbitofrontal cortex has been
reported (Volkow et al. 2001a). Furthermore, there seem to
be a significant negative correlation between the clinical
severity of psychotic symptoms and DAT density, and a
positive correlation between the duration of METH use and
the severity of psychotic symptoms, suggesting that chronic
METH use causes the reduction in DAT density, which may
directly contribute to the development of METH psychosis
(Iyo et al. 2004). Volkow et al. (2001b) also reported that
the chronic METH-induced reduction in DAT is associated
with motor and cognitive impairment. They found that
there was a negative correlation between the DAT reduc-
tions and the impaired motor performance, and a positive
correlation between the levels of DAT reductions and verbal
memory performance: the lower the dopamine (DA)
transporter level, the slower the motor responses, and the
greater worsening of memory performance. However,
because the reduced striatal DAT density tends to recover
following METH abstinence (>6 months) (Volkow et al.
2001b) while METH psychosis persists long after the
absence of METH use (Sato 1992), the direct and definite
link between DAT reduction and METH psychosis is still
lacking. It is possible that other permanent neuroadaptions
caused by DAT reduction also play a role. Other human
studies also reported that during the spontaneous recur-
rences of METH psychosis (referred to as “flashbacks”),
there were increases in plasma DA and norepinephrine
levels (Yui et al. 1999), consistent with the notion that
increased DA neurotransmission, coupled with increased
noradrenergic hyperactivity (due to stress) may contribute
to psychotic symptoms.
In contrast to limited research on human subjects, there
are many studies that have examined METH-induced brain
changes in rodents. Although many structural and neuro-
chemical changes induced by METH use/abuse has been
revealed, whether those changes are directly related to
MAP or even contributing to MAP is less certain. To ensure
that the neurochemical changes discussed here are poten-
tially relevant to the underpinnings of MAP, in this section,
we will narrow our discussion to research that has
demonstrated behavioral sensitization following human
patterns of METH abuse (e.g., chronic and escalating dose
regimens followed by repeated high-dose METH use).
Behavioral sensitization refers to a progressive increase in
motor and stereotypical responses to repeated drug treat-
ment (Martinez et al. 2005; Nestler 2001; Robinson and
Becker 1986). Thus, the acute effect of METH use is not
covered here. The rationale behind this approach is that
endogenous sensitized dopaminergic function (e.g., pro-
gressively enhanced DA supersensitivity) is believed to be
the critical cause of MAP (Ujike 2002; Ujike and Sato
2004). Because behavioral sensitization is the direct
“readout” of central DA sensitization, it becomes an
indispensable proxy measure of MAP. Because clinical
observations suggest that MAP (as well as other psychos-
timulant psychosis) often emerges after repeated high-dose
binges or runs, typically preceded by a more intermittent
and escalating pattern of METH abuse, animal models that
utilize a long-term intermittent and/or escalating dose
regimen, followed by repeated high-dose METH runs are
most likely to capture the clinical feature of MAP, and
afford us the best chance to identify the neurochemical
changes accompanied with MAP. Thus, studies utilizing this
approach will be emphasized.
Chronic treatment of METH causes an increase of
dopaminergic neurotransmission inthe striatum. For example,
Nishikawa et al. (1983) found that repeated METH treatment
(6 mg/kg per day for 3–14 days) produced a robust
behavioral sensitization in the form of augmented stereotypy.
A later challenge injection of a lower METH dose (2 mg/kg)
increased DA turnover (lower DA and higher 3, 4-
dihydroxyphenylacetic acid levels, higher ratios of 3, 4-
dihydroxyphenylacetic acid over DA) in the striatum and
mesolimbic area of the sensitized animals. Kazahaya et al.
(1989) also found that a challenge injection of METH after
7 days withdrawal from chronic administration of METH
(4 mg/kg for 14 days) markedly increased DA release in the
striatum. Segal and Kuczenski (1997) found that multiple
short-interval METH injections (four daily injections at 2-hr
intervals at 4.42 mg/kg) produced an augmented DA and
serotonin release in both the nucleus accumbens and
caudate-putamen in rats that were pretreated with METH
for 16 days. These findings, coupled with the findings that
repeated METH treatment directly sensitizes DA receptors in
the nucleus accumbens and ventral tegmental area (Amano et
al. 1996, 2003), and reduces striatal DAT (Izquierdo et al.
2010), strongly suggests that the enhanced striatal DA
neurotransmission (e.g. increased DA release and supersen-
sitivity of receptors) plays an important role in METH-
induced behavioral sensitization. As discussed earlier, phar-
macologic evidence is consistent with this finding. Ujike et
al. 1989 showed that pretreatment of SCH 23390 (a selective
D1 DA receptor antagonist) or YM-09151-2 (a selective D2
DA receptor antagonist) prevented the development of
behavioral sensitization induced by repeated METH injection
for 14daysand reduced the enhanced DA release produced
by METH challenge.
Chronic METH users often take the drug continuously,
and the plasma drug concentrations are elevated and
132 J Neuroimmune Pharmacol (2012) 7:113–139maintained throughout a 2–3 day binge. Studies simulating
this pattern of human METH use often employ an escalating
dose (ED)-multiple binge rodent model (Kuczenski et al.
2009; Segal and Kuczenski 1997, 1999). Kuczenski et al.
(2009) developed a computer-controlled, intravenous drug
delivery methodology with dynamic infusion which imposes
a 12-hour half-life of the drug in rats to reproduce a plasma
METH profile that approximates human METH pharmaco-
kinetics. Using this drug administration procedure, they still
found a prolonged elevation in caudate extracellular DA and
behavioral sensitization.
In addition to DA, chronic METH use also produces
changes in other neurotransmitter systems, which are also
implicated in METH-induced behavioral sensitization. For
example, it has been shown that repeated METH treatment
(3 mg/kg/day for 30–50 days) increased serotonin levels in
cats, which were restored by chlorpromazine treatment
(Utena 1966). Rats receiving single daily injections of
METH, followed by multiple runs (four daily injections at
2-hr intervals) showed a decrease in serotonin response in
the striatum during runs (Segal and Kuczenski 1997). The
findings that pretreatment with MDL 72222, a 5-HT3
antagonist, can attenuate both the development and expres-
sion of METH-induced behavioral sensitization (Yoo et al.
2006), and repeated treatment with aripiprazole (a drug
with 5-HT1A agonist action) during the withdrawal period
from repeated METH treatment attenuated METH-induced
behavioral sensitization (Futamura et al. 2010), also point
to the notion that serotonin-mediated neurotransmission are
related to the psychotomimetic effect of METH. Other
neurotransmitters implicated in METH sensitization include
substance P and sigma receptors, as evidenced by the
findings that repeated METH treatment decreased the
substance P receptor binding (Ujike et al. 1988) and sigma
receptor antagonist BMY 14802 prevents the development
of behavioral sensitization induced by repeated administra-
tion of METH (Ujike et al. 1992).
Conclusion
There is great need for increased research to further
understand factors related to MAP and how this psychosis
affects METH use, dependence, and treatment outcomes.
The current state of knowledge suggests that these factors,
and their interaction, will span genetic to socioenvironmen-
tal influences. As such, research directed at the better
understanding of MAP, by necessity, will need to be
translational. This review identifies some gaps in our
understanding and outlined potential future avenues of
research that could help realize this goal of better treatment
efficacy for METH-dependent individuals with MAP. For
instance, there are no studies assessing protective factors
for MAP, which may mitigate against risk factors for
psychosis. Does level of familial support, as an example,
during treatment affect symptom expression and/or treat-
ment outcome? Along these lines, there is a solid
foundation of genetics work that has identified several
candidate genes that may play a role in MAP development.
However, larger studies of more ethnically diverse popula-
tions that likely have unique risk and protective factors are
needed. Finally, advances in the development of animal
models that show etiological and predictive validity are
needed for a more complete understanding of the causes of
MAP. These models would likely assist in drug develop-
ment and behavioral interventions.
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